MONDAY, July 21 (HealthDay News) -- The controversial cholesterol drug Vytorin does not lower the risk of major heart valve problems, according to a report released Monday by its manufacturers, Schering-Plough Corp. and Merck & Co.

In a multi-country study of 1,873 patients, the drug was no better than placebo at lowering the odds of major cardiovascular events in patients suffering from aortic stenosis, a condition involving blocked blood flow to the heart.

SUNDAY, March 30 (HealthDay News) -- A divided cardiology community is trying once again to make sense of a trial showing that a drug can lower levels of "bad" LDL cholesterol and yet give no apparent benefit to people at high risk of heart attack and other cardiovascular problems.